Safety, Tolerability, and Pharmacokinetics of Inhaled ICF001 in Healthy Adults

Phase 1, randomised, double-blind trial of ICF001 (2 arms). Primary endpoints: Number of Participants With an Adverse Event (AE) up to 50 days, Number of Participants With Clinically Significant Change From Baseline in Local Tolerability Findings up to 50 days and 5 more. Planned start Sep 2026; status: not yet recruiting.